Ceftobiprole, an investigational cephalosporin, is currently in Phase III analytic development. Ceftobiprole as cefepime, is a anemic inducer and a poor substrate for AmpC Beta lactamases.Ceftobiprole medocaril, the prodrug ceftobiprole by claret esterases adapted ceftobiprole in <30 minutes.
Ceftobiprole is a broad-spectrum cephalosporin with approved action adjoin Gram-positive cocci, including methicillin-resistant Staphylococcus aureus in vitro action (MRSA) and methicillin-resistant S. epidermidis, S. pneumoniae aggressive to penicillin, Enterococcus faecalis, Gram-negative bacteria, including AmpC Escherichia coli and Pseudomonas aeruginosa, but not including beta-lactamase bearing strains of continued spectrum.
As cefotaxime, ceftriaxone, ceftazidime and cefepime, ceftobiprole shows bound action adjoin anaerobes as Bacteroides fragilis Bacteroides fragilis and not spp. In a footfall and consecutive access in vitro attrition development trials, ceftobiprole has approved a low ability to baddest for aggressive subpopulations.
Maximum serum concentrations of ceftobiprole were empiric at the end of a individual 30-minute infusion, 35.5 mug / ml for a 500 mg dosage and 59.6 mug / ml for a dosage of 750 mg. The aggregate of administration of Ceftobiprole is 0.26 l / kg (about 18 l), protein bounden is 16%, and the serum half-life is about 3.5 hours.